Updates and Insights on HER2 in Breast Cancer in Sohag Governorate

* To evaluate HER2 expression in breast carcinoma with emphasizing HER2-ultralow, and HER2-low, HER2 equivocal tumors. * To correlate the results of HER2 with clinico-pathological prognostic parameters; examples tumor grade, Ki-67 proliferation index, nodal status, tumor size, lympho-vascular invasion, and perineural invasion, tumor infiltrating lymphocytes * To access interobserval agreement in HER2 score interpretation

NCT Number	NCT07758127
Lead Sponsor	Sohag University Collaborators: Sohag Oncology Center
Conditions	HER2 Status in Breast Cancer
Enrollment	100 participants
Start Date	2026-09
Primary Completion	2027-09 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-12